The more I read the more faults I find
Cellestis commenced sales of the second generation of its QuantiFERON range seven years ago. As the second generation product and the current generation product, QuantiFERON-TB Gold In-Tube gained acceptance in the market
It would seem that Qiagen support this style of "analysis"
The views put forward by some retail shareholders are flawed and misleading. Shareholders now have a validated analysis to make fully informed decisions," said a Qiagen official.
But of course, they would say that. Howabout repudiating CST?
